Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterNo recent work listed

John Parker Hoffman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8176-8190; OpenAlex author ID A5086171527, A5109346484. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 3, last author 4)
Trials
1
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2003: 1 trial · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 3 papers · 2012: 1 paper · 2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 5 papers · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 24

  1. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-021-10219-3↗
  2. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  3. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  4. Biliary microbiome in pancreatic cancer: alterations with neoadjuvant therapy. Co-author DOI 10.1016/j.hpb.2019.04.005↗
  5. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000227↗
  6. The Utility of Preoperative Vascular Grading in Patients Undergoing Surgery First for Pancreatic Cancer: Does Radiologic Arterial or Venous Involvement Predict… Co-author DOI 10.1155/2018/7675262↗
  7. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  8. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy… Co-author DOI 10.1016/j.ijrobp.2015.10.062↗
  9. Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer. Co-author DOI 10.1016/j.prro.2015.11.005↗
  10. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0149↗
  11. Is It Time for Total Neoadjuvant Therapy for Patients With Resectable Pancreatic Adenocarcinoma? Co-author DOI 10.1200/jop.2016.016352↗
  12. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Co-author DOI 10.1016/j.prro.2015.04.004↗
  13. Morbidity among long-term survivors after pancreatoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1245/s10434-014-3969-y↗
  14. Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. First author DOI 10.6004/jnccn.2015.0079↗
  15. Potential prognostic biomarkers of pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182a6867e↗
  16. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. First author DOI 10.1111/hpb.12058↗
  17. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery ma… Last author DOI 10.1245/s10434-013-3396-5↗
  18. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  19. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. First author DOI 10.1016/j.celrep.2013.05.036↗
  20. How to define and manage borderline resectable pancreatic cancer. Last author DOI 10.1016/j.suc.2013.02.005↗
  21. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗
  22. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for panc… Co-author DOI 10.1016/j.ijrobp.2010.07.1993↗
  23. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S… Co-author DOI 10.1245/s10434-011-1630-6↗
  24. Significance of pathologic response to preoperative therapy in pancreatic cancer. Last author DOI 10.1245/s10434-011-2086-4↗

Trials 1

  1. Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer Study chair NCT00049348↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joshua E. Meyer · 7 shared papers, 2014–2022 · strength 0.54
  2. Steven J. Cohen · 9 shared papers, 2011–2022 · strength 0.53
  3. Sanjay S. Reddy · 4 shared papers, 2016–2022 · strength 0.48
  4. Talha Shaikh · 4 shared papers, 2015–2022 · strength 0.36
  5. William F. Regine · 5 shared papers, 2011–2021 · strength 0.29
  6. Ross Allen Abrams · 5 shared papers, 2011–2021 · strength 0.29
  7. Howard P. Safran · 5 shared papers, 2011–2021 · strength 0.29
  8. Christopher H. Crane · 3 shared papers, 2016–2021 · strength 0.24
  9. Lora S. Wang · 3 shared papers, 2015–2018 · strength 0.22
  10. Neha Goel · 2 shared papers, 2018–2019 · strength 0.21
  11. Al B. Benson · 5 shared papers, 2011–2021 · strength 0.21
  12. Kathryn T. Chen · 3 shared papers, 2014–2015 · strength 0.17
  13. Joseph M. Herman · 4 shared papers, 2012–2016 · strength 0.16
  14. Eddie Zhang · 1 shared paper, 2022 · strength 0.15
  15. Efrat Dotan · 1 shared paper, 2022 · strength 0.15
  16. Yun Shin Chun · 3 shared papers, 2011–2014 · strength 0.14
  17. Henry Anthony Pitt · 1 shared paper, 2019 · strength 0.12
  18. Robert A. Wolff · 3 shared papers, 2012–2015 · strength 0.12
  19. Sarah P. Thayer · 3 shared papers, 2012–2015 · strength 0.12
  20. Pavlos Papavasiliou · 2 shared papers, 2013–2014 · strength 0.11
  21. Theodore Sunki Hong · 1 shared paper, 2021 · strength 0.11
  22. John Peter Plastaras · 1 shared paper, 2021 · strength 0.11
  23. Danielle S. Bitterman · 1 shared paper, 2021 · strength 0.11
  24. Charles S. Fuchs · 1 shared paper, 2021 · strength 0.11
  25. Mary F. Mulcahy · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.